Work

Clinical genomic and quantitative IHC–driven target identification to enable precision, tumor-selective activation of SynchroLINK T2X antibody-drug conjugates.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e15043

Authors: Steven Albert Everett, Craig Alan Coburn, Sohrob Daniel Doroodian, Kiana Hope Everett, Matthew Dean Zuck, Michael Victor Zuck

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162693299

Cites:

Cited by:

Related to: